<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="publisher-id">jbpneu</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26982047</article-id>
      <article-id pub-id-type="pmc">4805393</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37562016000000003</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta Ao Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Idiopathic pulmonary fibrosis can be a transient diagnosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Martina Rodrigues</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Daniel Antunes Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Ol&#xED;via Meira</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kairalla</surname>
            <given-names>Ronaldo Adib</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Carlos Roberto Ribeiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baldi</surname>
            <given-names>Bruno Guedes</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <aff id="aff1"><label>1</label>. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor - Hospital das Cl&#xED;nicas, Faculdade de Medicina, Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil.</aff>
      </contrib-group>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Feb</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2016</year>
      </pub-date>
      <volume>42</volume>
      <issue>1</issue>
      <fpage>74</fpage>
      <lpage>75</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="9"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>TO THE EDITOR:</title>
      <p>Usual interstitial pneumonia (UIP) can be accompanied by various clinical conditions, probably the most important of which is idiopathic pulmonary fibrosis (IPF), although the exact incidence and prevalence of IPF, in Brazil or elsewhere, remains unknown.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>-</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup> The diagnosis of IPF can be established only after the exclusion of other diseases potentially associated with the UIP pattern, such as chronic hypersensitivity pneumonitis, connective tissue diseases, especially rheumatoid arthritis, drug toxicity, and asbestosis.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>,</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>,</sup>
<xref rid="B05" ref-type="bibr">5</xref>
<sup>)</sup> The association between antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis and interstitial lung disease (ILD) has recently been described, including another possible etiology for the UIP pattern. Here, we report the case of a patient with an initial diagnosis of IPF who later developed ANCA-positive vasculitis.</p>
      <p>A 62-year-old nonsmoking male patient, a bricklayer, presented with a one-year history of dry cough and slowly progressive dyspnea, classified as grade 2 on the modified Medical Research Council scale. He was being treated with omeprazole, bromopride, and simvastatin for gastroesophageal reflux disease and dyslipidemia. Pulmonary auscultation revealed crackles at both lung bases, and the SpO<sub>2</sub> was 97% on room air. The findings of an HRCT scan of the chest (<xref ref-type="fig" rid="f01">Figure 1</xref>) were consistent with a UIP pattern. Pulmonary function tests revealed a mild restrictive pattern (FVC, 78% of predicted/3.6 L; FEV<sub>1</sub>, 81% of predicted/2.8 L; FEV<sub>1</sub>/FVC ratio, 0.78; and total lung capacity, 75% of predicted/5.25 L) with normal DLCO (92% of predicted/27.6 mL/min/mmHg). During a six-minute walk test, there was no desaturation (minimum SpO<sub>2</sub>, 96%), and the six-minute walk distance was 548 m.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Chest HRCT scans showing findings consistent with the pattern of usual interstitial pneumonia: A) discrete subpleural reticular opacities in the upper lobes; B) subpleural reticular opacities and discrete areas of ground-glass abnormalities at the level of the carina; C) peripheral reticular opacities, traction bronchiolectasis, and discrete areas of ground-glass abnormalities predominantly in the lower lobes; and D) peripheral honeycombing and traction bronchiolectasis in the lower lobes.</title></caption><graphic xlink:href="1806-3713-jbpneu-42-01-00074-gf01"/></fig>
</p>
      <p>The results of laboratory tests were normal, and autoantibody tests were negative, including tests for rheumatoid factor, antinuclear antibodies, anti-Jo-1, anti-Scl-70, and ANCA. The findings of a transthoracic echocardiogram were also normal. A surgical lung biopsy performed at another institution was reviewed and was found to show the UIP histopathological pattern, confirming the diagnosis of IPF. At that time, the patient was still under treatment for gastroesophageal reflux disease. </p>
      <p>After one year of clinical stability, the patient was admitted to the hospital with a one-month history of daily fever (38&#xB0;C) and hematuria, together with swelling and purple lesions in the lower limbs. Laboratory tests revealed anemia (hemoglobin, 9.5 g/dL), elevated C-reactive protein (155 mg/L; reference range, &lt; 5 mg/L) and elevated creatinine (4.5 mg/dL; estimated creatinine clearance, 14 mL/min). Urinalysis showed hematuria, proteinuria, and leukocyturia. There were also a mild reduction in complement C3 (86 mg/dL; reference range, 90-180 mg/dL) and C4 (9.6 mg/dL, reference range, 10-40 mg/dL), as well as positivity for myeloperoxidase-ANCA (1/320), antinuclear antibodies (1/320, with fine-speckled nuclear staining pattern), and rheumatoid factor (97 IU/mL).</p>
      <p>A new kidney biopsy was performed, and the analysis of the biopsy sample confirmed the diagnosis of pauci-immune crescentic glomerulonephritis associated with microscopic polyangiitis (MPA), and a skin biopsy of the lower limbs showed leukocytoclastic vasculitis. Methylprednisolone pulse therapy was administered at 1 g/day for three days, after which the patient was started on prednisone at a dose of 1 mg/day that was gradually tapered thereafter. Subsequent treatment with mycophenolate (1.5 g/day) produced gradual clinical improvement. After two years of treatment, the patient continued to have mild dyspnea (modified Medical Research Council scale grade 1), to show normal kidney function, and to test negative for ANCA, and well as to have stable HRCT and pulmonary function test findings. </p>
      <p>In patients with ANCA-positive vasculitis, particularly MPA, ILD is an uncommon finding and usually affects older men, with myeloperoxidase-ANCA and a UIP pattern on histopathology. However, the pathophysiology of the association of ILD and ANCA-positive vasculitis has not been fully elucidated.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>
</p>
      <p>Recent studies have demonstrated that there is a subset of IPF patients who are ANCA-positive at diagnosis or who convert to ANCA positivity during follow-up and subsequently develop MPA.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>,</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup> Kagiyama et al.<sup>(</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup> evaluated ANCA positivity and the incidence of MPA in 504 patients with IPF. The authors found that 36 (7%) of the patients were ANCA-positive at diagnosis of IPF. Of the 264 patients who were subsequently tested, 29 (11%) converted to ANCA positivity during the first five years of follow-up. Of the 35 patients who were either ANCA-positive at diagnosis or subsequently converted to ANCA positivity, 9 were diagnosed with MPA.</p>
      <p>Two drugs, nintedanib and pirfenidone, both of which slow the decline in lung function, were recently approved for the treatment of IPF.<sup>(</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> However, to date, there is no recommendation regarding the use of those drugs in patients with ILD associated with ANCA-positive vasculitis, in whom it has been suggested that the use of corticosteroids plus cyclophosphamide or rituximab is a better approach.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> The combination of mycophenolate and corticosteroids can also be considered.</p>
      <p>The prognosis of patients with ILD associated with ANCA-positive vasculitis has not been fully established. In a study of 49 such patients (82% with MPA), mortality was 34% in the first 60 months after the diagnosis. In a review of 65 patients (85% with a UIP pattern) that were followed for 45 months, 35% showed progression of ILD and the remaining 65% showed stability or improvement,<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> which suggests that the prognosis of ILD associated with ANCA-positive vasculitis is better than is that of IPF.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>
</p>
      <p>In conclusion, this report underscores the potential for the occurrence of ILD, including a UIP pattern, in patients with ANCA-positive vasculitis. In that form of vasculitis, interstitial lung involvement can precede systemic manifestations and patients can be initially diagnosed with IPF. We emphasize the importance of an extensive etiological investigation of patients who show a UIP pattern, especially of those in whom the disease has an indolent course. The diagnosis of a secondary cause could facilitate the definition of the best therapeutic strategy and the determination of the prognosis in such patients. </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raghu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Collard</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Egan</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KK</given-names>
            </name>
          </person-group>
          <article-title>An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2011</year>
          <volume>183</volume>
          <issue>6</issue>
          <fpage>788</fpage>
          <lpage>824</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.2009-040GL</pub-id>
          <pub-id pub-id-type="pmid">21471066</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baddini-Martinez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Baldi</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Jezler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Rufino</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Update on diagnosis and treatment of idiopathic pulmonary fibrosis</article-title>
          <source>J Bras Pneumol</source>
          <year>2015</year>
          <volume>41</volume>
          <issue>5</issue>
          <fpage>454</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="doi">10.1590/S1806-37132015000000152</pub-id>
          <pub-id pub-id-type="pmid">26578138</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baddini-Martinez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>How many patients with idiopathic pulmonary fibrosis are there in Brazil</article-title>
          <source>J Bras Pneumol</source>
          <year>2015</year>
          <volume>41</volume>
          <issue>6</issue>
          <fpage>560</fpage>
          <lpage>561</lpage>
          <pub-id pub-id-type="doi">10.1590/S1806-37562015000000165</pub-id>
          <pub-id pub-id-type="pmid">26785967</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wuyts</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Cavazza</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sverzellati</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Spagnolo</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?</article-title>
          <source>Eur Respir Rev</source>
          <year>2014</year>
          <volume>23</volume>
          <issue>133</issue>
          <fpage>308</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1183/09059180.00004914</pub-id>
          <pub-id pub-id-type="pmid">25176967</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dalurzo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Panse</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Parish</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Leslie</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies<bold>. </bold>Clinical, radiological and histopathological clues to aetiology</article-title>
          <source>J Clin Pathol</source>
          <year>2013</year>
          <volume>66</volume>
          <issue>10</issue>
          <fpage>896</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="doi">10.1136/jclinpath-2013-201442</pub-id>
          <pub-id pub-id-type="pmid">23703852</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Comarmond</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Crestani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tazi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hervier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Adam-Marchand</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nunes</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis</article-title>
          <source>Medicine (Baltimore)</source>
          <year>2014</year>
          <volume>93</volume>
          <issue>24</issue>
          <fpage>340</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="doi">10.1097/MD.0000000000000217</pub-id>
          <pub-id pub-id-type="pmid">25500703</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kagiyama</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takayanagi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kanauchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishiguro</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yanagisawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sugita</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis</article-title>
          <source>BMJ Open Respir Res</source>
          <year>2015</year>
          <volume>2</volume>
          <issue>1</issue>
          <elocation-id/>
          <pub-id pub-id-type="doi">10.1136/bmjresp-2014-000058</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>TE</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Bradford</surname>
              <given-names>WZ</given-names>
            </name>
            <name>
              <surname>Castro-Bernardini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fagan</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Glaspole</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Glassberg</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
          <article-title>A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <issue>22</issue>
          <fpage>2083</fpage>
          <lpage>2092</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1402582</pub-id>
          <pub-id pub-id-type="pmid">24836312</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richeldi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Raghu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Azuma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Costabel</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and Safety of nintedanib in idiopathic pulmonary fibrosis</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <issue>22</issue>
          <fpage>2071</fpage>
          <lpage>2082</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1402584</pub-id>
          <pub-id pub-id-type="pmid">24836310</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Carta Ao Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fibrose pulmonar idiop&#xE1;tica pode ser um diagn&#xF3;stico transit&#xF3;rio</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Martina Rodrigues de</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Daniel Antunes Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Ol&#xED;via Meira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kairalla</surname>
            <given-names>Ronaldo Adib</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Carlos Roberto Ribeiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baldi</surname>
            <given-names>Bruno Guedes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">
<sup>1</sup>
</xref>
        </contrib>
        <aff id="aff01"><label>1</label>. Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o - InCor - Hospital das Cl&#xED;nicas, Faculdade de Medicina, Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
      </contrib-group>
    </front-stub>
    <body>
      <sec>
        <title>AO EDITOR:</title>
        <p>A pneumonia intersticial usual (PIU) pode ser acompanhada de diversas condi&#xE7;&#xF5;es cl&#xED;nicas, das quais a mais importante provavelmente seja a fibrose pulmonar idiop&#xE1;tica (FPI), embora a exata incid&#xEA;ncia e preval&#xEA;ncia de FPI, no Brasil ou em outras localidades, permane&#xE7;a desconhecida.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>-</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup> O diagn&#xF3;stico de FPI pode ser estabelecido apenas ap&#xF3;s a exclus&#xE3;o de outras doen&#xE7;as potencialmente associadas ao padr&#xE3;o de PIU, tais como pneumonite de hipersensibilidade cr&#xF4;nica, doen&#xE7;as do tecido conjuntivo, especialmente artrite reumatoide, toxicidade por drogas e asbestose.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>,</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>,</sup>
<xref rid="B05" ref-type="bibr">5</xref>
<sup>)</sup> A associa&#xE7;&#xE3;o entre vasculite <italic>antineutrophil cytoplasmic antibody</italic> (ANCA, anticorpo anticitoplasma de neutr&#xF3;filos) positiva e doen&#xE7;a pulmonar intersticial (DPI) foi descrita recentemente, incluindo outra poss&#xED;vel etiologia para o padr&#xE3;o de PIU. Relatamos aqui o caso de um paciente com diagn&#xF3;stico inicial de FPI que posteriormente desenvolveu vasculite ANCA positiva.</p>
        <p>Paciente de 62 anos, do sexo masculino, n&#xE3;o fumante, pedreiro, apresentava hist&#xF3;ria de tosse seca e dispneia lentamente progressiva, classificada como grau 2 na escala modificada do <italic>Medical Research Council</italic>, h&#xE1; um ano. Estava em uso de omeprazol, bromoprida e sinvastatina para tratamento de doen&#xE7;a do refluxo gastroesof&#xE1;gico e dislipidemia. A ausculta pulmonar revelou estertores crepitantes bibasais, e a SpO<sub>2</sub> era de 97% em ar ambiente. Os achados de TCAR de t&#xF3;rax (<xref ref-type="fig" rid="f1">Figura 1</xref>) eram compat&#xED;veis com o padr&#xE3;o de PIU. Os testes de fun&#xE7;&#xE3;o pulmonar revelaram padr&#xE3;o restritivo leve (CVF, 78% do previsto/3,6 l; VEF<sub>1</sub>, 81% do previsto/2,8 l; rela&#xE7;&#xE3;o VEF<sub>1</sub>/CVF, 0,78; e capacidade pulmonar total, 75% do previsto/5,25 l) com DLCO normal (92% do previsto/27,6 ml/min/mmHg). Durante o teste de caminhada de seis minutos, n&#xE3;o houve dessatura&#xE7;&#xE3;o (SpO<sub>2</sub> m&#xED;nima, 96%), e a dist&#xE2;ncia percorrida foi de 548 m.</p>
        <p>
<fig id="f1" orientation="portrait" position="float"><label>Figura 1.</label><caption><title>Imagens de TCAR de t&#xF3;rax mostrando achados compat&#xED;veis com o padr&#xE3;o de pneumonia intersticial usual: A) discretas opacidades reticulares subpleurais nos lobos superiores; B) opacidades reticulares subpleurais e discretas &#xE1;reas de anormalidade em vidro fosco no n&#xED;vel da carina; C) opacidades reticulares perif&#xE9;ricas, bronquiolectasias de tra&#xE7;&#xE3;o e discretas &#xE1;reas de anormalidade em vidro fosco predominantemente nos lobos inferiores; e D) faveolamento perif&#xE9;rico e bronquiolectasias de tra&#xE7;&#xE3;o nos lobos inferiores.</title></caption><graphic xlink:href="1806-3713-jbpneu-42-01-00074-gf01-pt"/></fig>
</p>
        <p>Os resultados dos exames laboratoriais foram normais, e os testes de autoanticorpos foram negativos, inclusive os testes para fator reumatoide, anticorpos antinucleares, anti-Jo-1, anti-Scl-70 e ANCA. Os achados do ecocardiograma transtor&#xE1;cico tamb&#xE9;m foram normais. A revis&#xE3;o da bi&#xF3;psia pulmonar cir&#xFA;rgica realizada em outra institui&#xE7;&#xE3;o demonstrou padr&#xE3;o histopatol&#xF3;gico de PIU, confirmando o diagn&#xF3;stico de FPI. Na &#xE9;poca, o paciente ainda estava em tratamento para doen&#xE7;a do refluxo gastroesof&#xE1;gico.</p>
        <p>Ap&#xF3;s um ano de estabilidade cl&#xED;nica, o paciente foi internado com hist&#xF3;ria de febre di&#xE1;ria (38&#xB0;C) e hemat&#xFA;ria h&#xE1; um m&#xEA;s, juntamente com incha&#xE7;o e les&#xF5;es arroxeadas nos membros inferiores. Os exames laboratoriais revelaram anemia (hemoglobina, 9,5 g/dl), prote&#xED;na C reativa elevada (155 mg/l; intervalo de refer&#xEA;ncia, &lt; 5 mg/l) e creatinina elevada (4,5 mg/dl; <italic>clearance</italic> estimado de creatinina, 14 ml/min). O exame de urina tipo 1 mostrou hemat&#xFA;ria, protein&#xFA;ria e leucocit&#xFA;ria. Tamb&#xE9;m houve uma leve diminui&#xE7;&#xE3;o de C3 (86 mg/dl; intervalo de refer&#xEA;ncia, 90-180 mg/dl) e C4 (9,6 mg/dl, intervalo de refer&#xEA;ncia, 10-40 mg/dl), assim como positividade de ANCA antimieloperoxidase (1/320), anticorpos antinucleares (1/320, com padr&#xE3;o de colora&#xE7;&#xE3;o nuclear pontilhada fina) e fator reumatoide (97 UI/ml).</p>
        <p>Realizou-se nova bi&#xF3;psia renal, sendo que a an&#xE1;lise da amostra da bi&#xF3;psia confirmou o diagn&#xF3;stico de glomerulonefrite cresc&#xEA;ntica pauci-imune associada a poliangiite microsc&#xF3;pica (PAM), e a bi&#xF3;psia de tecido de membros inferiores demonstrou vasculite leucocitocl&#xE1;stica. Foi administrada pulsoterapia com metilprednisolona 1 g/dia por tr&#xEA;s dias e, em seguida, foi iniciado tratamento com prednisona na dose de 1 mg/dia, a qual foi gradualmente reduzida. O tratamento posterior com micofenolato (1,5 g/dia) produziu melhora cl&#xED;nica gradual. Ap&#xF3;s dois anos de tratamento, o paciente continuava apresentando dispneia leve (grau 1 na escala modificada do <italic>Medical Research Council</italic>), fun&#xE7;&#xE3;o renal normal e negatividade de ANCA, assim como achados de TCAR e resultados de testes de fun&#xE7;&#xE3;o pulmonar est&#xE1;veis.</p>
        <p>Em pacientes com vasculite ANCA positiva, particularmente PAM, a DPI &#xE9; um achado incomum e geralmente afeta homens mais velhos, com ANCA antimieloperoxidase e padr&#xE3;o de PIU na histopatologia. Por&#xE9;m, a fisiopatologia da associa&#xE7;&#xE3;o de DPI e vasculite ANCA positiva ainda n&#xE3;o foi totalmente elucidada.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>
</p>
        <p>Estudos recentes demonstraram que h&#xE1; um subconjunto de pacientes com FPI que s&#xE3;o ANCA positivos no momento do diagn&#xF3;stico ou que apresentam convers&#xE3;o para positividade de ANCA durante o acompanhamento e posteriormente desenvolvem PAM.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>,</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup> Kagiyama et al.<sup>(</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup> avaliaram a positividade de ANCA e a incid&#xEA;ncia de PAM em 504 pacientes com FPI. Os autores constataram que 36 (7%) dos pacientes eram ANCA positivos no momento do diagn&#xF3;stico de FPI. Dos 264 pacientes que foram posteriormente testados, 29 (11%) apresentaram convers&#xE3;o para positividade de ANCA durante os primeiros cinco anos de acompanhamento. Dos 35 pacientes que eram ANCA positivos no momento do diagn&#xF3;stico ou que posteriormente apresentaram convers&#xE3;o para positividade de ANCA, 9 foram diagnosticados com PAM. Dois medicamentos, o nintedanibe e a pirfenidona, ambos os quais retardam o decl&#xED;nio da fun&#xE7;&#xE3;o pulmonar, foram recentemente aprovados para o tratamento da FPI.<sup>(</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>,</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup> Por&#xE9;m, at&#xE9; hoje, n&#xE3;o h&#xE1; nenhuma recomenda&#xE7;&#xE3;o sobre o uso desses medicamentos em pacientes com DPI associada a vasculite ANCA positiva, para os quais o uso de corticosteroides mais ciclofosfamida ou rituximabe foi sugerido como melhor abordagem.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> Pode-se tamb&#xE9;m considerar a combina&#xE7;&#xE3;o de micofenolato e corticosteroides.</p>
        <p>O progn&#xF3;stico de pacientes com DPI associada a vasculite ANCA positiva ainda n&#xE3;o foi totalmente estabelecido. Em um estudo com 49 desses pacientes (82% com PAM), a mortalidade foi de 34% nos primeiros 60 meses ap&#xF3;s o diagn&#xF3;stico. Em uma revis&#xE3;o com 65 pacientes (85% com padr&#xE3;o de PIU) que foram acompanhados por 45 meses, 35% apresentaram progress&#xE3;o da DPI e os 65% restantes apresentaram estabilidade ou melhora,<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup> o que sugere que o progn&#xF3;stico da vasculite ANCA positiva &#xE9; melhor do que o da FPI.<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>
</p>
        <p>Em conclus&#xE3;o, este relato destaca o potencial para a ocorr&#xEA;ncia de DPI, inclusive do padr&#xE3;o de PIU, em pacientes com vasculite ANCA positiva. Nessa forma de vasculite, o acometimento pulmonar intersticial pode preceder as manifesta&#xE7;&#xF5;es sist&#xEA;micas e os pacientes podem ser inicialmente diagnosticados com FPI. Ressaltamos a import&#xE2;ncia de uma extensa investiga&#xE7;&#xE3;o etiol&#xF3;gica dos pacientes que apresentam padr&#xE3;o de PIU, especialmente daqueles nos quais a doen&#xE7;a tem um curso indolente. O diagn&#xF3;stico de uma causa secund&#xE1;ria pode facilitar a defini&#xE7;&#xE3;o da melhor estrat&#xE9;gia terap&#xEA;utica e a determina&#xE7;&#xE3;o do progn&#xF3;stico desses pacientes.</p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
